
Affimed N.V. AFMD
Quartalsbericht 2022-Q2
hinzugefügt 11.08.2022
Affimed N.V. Operativer Cashflow 2011-2026 | AFMD
Operativer Cashflow Jährlich Affimed N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -86.6 M | -19.4 M | -29.1 M | 49.4 M | -25.5 M | -32.1 M | -18.5 M | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 49.4 M | -86.6 M | -23.1 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M | ||
|
Adagene
ADAG
|
-29.7 M | $ 2.38 | 17.22 % | $ 134 M | ||
|
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | ||
|
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 2.99 | 0.74 % | $ 908 M | ||
|
BioNTech SE
BNTX
|
890 M | $ 115.72 | -2.32 % | $ 27.2 B | ||
|
BioXcel Therapeutics
BTAI
|
-72 M | $ 1.82 | 0.55 % | $ 4.61 M | ||
|
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | ||
|
Burford Capital Limited
BUR
|
181 M | $ 9.72 | -1.57 % | $ 1.55 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.31 | 1.22 % | $ 7.96 B | ||
|
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 4.4 | 5.77 % | $ 9.57 B | ||
|
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
213 M | $ 25.88 | -1.01 % | $ 1.25 B | ||
|
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | ||
|
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
198 M | $ 43.14 | 4.46 % | $ 4.45 B | ||
|
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | ||
|
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
240 M | $ 23.9 | -2.27 % | $ 2.83 B | ||
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | ||
|
Ascendis Pharma A/S
ASND
|
-418 M | $ 231.39 | 1.2 % | $ 5 B | ||
|
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | ||
|
Aytu BioScience
AYTU
|
-1.94 M | $ 2.72 | 0.18 % | $ 17.1 M | ||
|
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
180 M | $ 68.21 | -1.98 % | $ 9.12 B | ||
|
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | ||
|
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | ||
|
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | ||
|
Coherus BioSciences
CHRS
|
-175 M | $ 2.05 | 28.93 % | $ 193 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | ||
|
Biogen
BIIB
|
2.88 B | $ 171.06 | -1.58 % | $ 24.9 B | ||
|
Bio-Path Holdings
BPTH
|
-11.5 M | - | - | $ 100 K | ||
|
BioVie
BIVI
|
-19 M | $ 1.24 | -0.8 % | $ 1.83 M | ||
|
Baudax Bio
BXRX
|
-27.8 M | - | 0.59 % | $ 63 K | ||
|
Calithera Biosciences
CALA
|
-66.3 M | - | -10.95 % | $ 876 K |